GlycoNAVI: CheGly (Chemical Glycosylation)
ACT

Trioxacarcin C

ID Compound Name Target Name Species Assay Method Activity Value Conditions DOI
act777Trioxacarcin CStaphylococcus aureus ATCC 6538PMIC (μg/ml)0.410.7164/antibiotics.34.1525
act780Trioxacarcin CBacillus subtilis No. 10707MIC (μg/ml)0.0110.7164/antibiotics.34.1525
act783Trioxacarcin CKlebsiella pneumoniae ATCC 10031MIC (μg/ml)1.510.7164/antibiotics.34.1525
act786Trioxacarcin CSalmonella typhosa ATCC 9992MIC (μg/ml)>10010.7164/antibiotics.34.1525
act789Trioxacarcin CEscherichia coli ATCC 26MIC (μg/ml)5010.7164/antibiotics.34.1525
act797Trioxacarcin Cmurine sarcoma 180 (s.c. - i.p.)Dose (mg/kg)\nTumor volume (mm3)\nT/C1.0 493 0.3510.7164/antibiotics.34.1525
act798Trioxacarcin Cmurine sarcoma 180 (s.c. - i.p.)Dose (mg/kg)\nTumor volume (mm3)\nT/C0.5 1170 0.8310.7164/antibiotics.34.1525
act810Trioxacarcin Cmurine leukemia P388 (i.p. - i.p.).Dose (mg/kg)\nSurvival days\nIncrease of life span (%)1.0 13.1 2510.7164/antibiotics.34.1525
act811Trioxacarcin Cmurine leukemia P388 (i.p. - i.p.).Dose (mg/kg)\nSurvival days\nIncrease of life span (%)0.5 14.0 3310.7164/antibiotics.34.1525
act812Trioxacarcin Cmurine leukemia P388 (i.p. - i.p.).Dose (mg/kg)\nSurvival days\nIncrease of life span (%)0.25 13.3 2710.7164/antibiotics.34.1525
act815Trioxacarcin CEscherichia coliBacteriaagar diffusion test with 30-40μg/paper disk (9mmφ), \ndiameter of inhibition zones in [mm]3010.7164/antibiotics.34.1525
act820Trioxacarcin CBacillus subtilisBacteriaagar diffusion test with 30-40μg/paper disk (9mmφ), \ndiameter of inhibition zones in [mm]3810.7164/antibiotics.34.1525
act825Trioxacarcin CStaphylococcus viridochromogenes Tu 57Bacteriaagar diffusion test with 30-40μg/paper disk (9mmφ), \ndiameter of inhibition zones in [mm]2410.7164/antibiotics.34.1525
act830Trioxacarcin CStaphylococcus aureusBacteriaagar diffusion test with 30-40μg/paper disk (9mmφ), \ndiameter of inhibition zones in [mm]2210.7164/antibiotics.34.1525
act835Trioxacarcin CPlasmodium falciparumPlasmodiumIC50 K1\nIC50 NF54>5000 n.d. >5000 n.d.10.7164/antibiotics.34.1525
act839Trioxacarcin CHT-29TumorIC70 values (μg/ml)<0.310.7164/antibiotics.34.1525
act843Trioxacarcin CSF-268TumorIC70 values (μg/ml)0.00610.7164/antibiotics.34.1525
act847Trioxacarcin CH-460TumorIC70 values (μg/ml)<0.000310.7164/antibiotics.34.1525
act851Trioxacarcin CLXFA 526LTumorIC70 values (μg/ml)<0.310.7164/antibiotics.34.1525
act855Trioxacarcin CLXFL 529LTumorIC70 values (μg/ml)0.01610.7164/antibiotics.34.1525
act859Trioxacarcin CMCF-7TumorIC70 values (μg/ml)0.00210.7164/antibiotics.34.1525
act863Trioxacarcin CMEXF 514LTumorIC70 values (μg/ml)0.13910.7164/antibiotics.34.1525
act867Trioxacarcin CPC3MTumorIC70 values (μg/ml)0.03510.7164/antibiotics.34.1525
act871Trioxacarcin CRXF 631LTumorIC70 values (μg/ml)0.11810.7164/antibiotics.34.1525
act875Trioxacarcin Clarge cell lung cancer xenograft LXFL 529 in vitroTumorIC50 values (μg/ml)\nIC70 values (μg/ml)\nIC90 values (μg/ml)<0.003 0.33 1.010.7164/antibiotics.34.1525